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Renal cell tumors (RCT) collectively constitute the thirdmost common type of genitourinary
neoplasms, only surpassed by prostate and bladder cancer. They comprise a heteroge-
neous group of neoplasms with distinctive clinical, morphological, and genetic features.
Epigenetic alterations are a hallmark of cancer cells and their role in renal tumorigenesis
is starting to emerge. Aberrant DNA methylation, altered chromatin remodeling/histone
onco-modiﬁcations and deregulated microRNA expression not only contribute to the emer-
gence and progression of RCTs, but owing to their ubiquity, they also constitute a promising
class of biomarkers tailored for disease detection, diagnosis, assessment of prognosis, and
prediction of response to therapy. Moreover, due to their dynamic and reversible proper-
ties, those alterations represent a target for epigenetic-directed therapies. In this review,
the current knowledge about epigenetic mechanisms and their altered status in RCT is
summarized and their envisaged use in a clinical setting is also provided.
Keywords: epigenetics, kidney, renal cell tumors, DNA methylation, chromatin remodeling, histone post-
translational modifications, microRNAs, epigenetic-based therapeutics
INTRODUCTION
Renal cell tumors (RCT) are the most common neoplasms of the
kidney in adults, representing 2–3% of all non-cutaneous malig-
nant neoplasms, ranking 14th in incidence for both genders,with a
mortality rate of 1.6/100,000,worldwide (Ferlay et al., 2010). RCTs
are a very heterogeneous groupof neoplasms, ranging frombenign
to malignant behavior, displaying variable clinical aggressiveness
and considerable histopathological diversity (Lopez-Beltran et al.,
2009). The most prevalent benign RCT is oncocytoma, whereas
among malignant RCTs the most common subtypes are clear
cell renal cell carcinoma (ccRCC, 70–75% of cases), papillary
renal cell carcinoma (pRCC, 10–15% of cases), and chromophobe
renal cell carcinoma (chRCC, 5–10% of cases). Owing to the
fact that RCT are mostly asymptomatic at their earliest stages,
when curative treatment is more likely to be effective, a signiﬁ-
cant proportion of cases (up to a third of all RCCs) are diagnosed
at a late stage, when the neoplasm has already spread locally or
systemically (Lam et al., 2005). On the other hand, an increas-
ing number of RCT is being identiﬁed through routine ultra-
sonography, posing new diagnostic challenges at a pre-operative
stage, such as the discrimination between benign and malignant
tumors.
Presently, there are no effective screening or early diagnos-
tic tools for RCT that might be used in at-risk groups or
in a wider population setting (Rini et al., 2009). However,
the development of such tools might have a relevant clini-
cal impact, mainly if they would be based on non-invasive
approaches (Scelo and Brennan, 2007). In this regard, cancer-
related genetic and/or epigenetic alterations might be used as
biomarkers enabling the detection of cancerous cells in clin-
ical samples, thus increasing the ability to identify tumors at
their earliest stages (Esteller, 2008). Eventually, those alterations
might also prove useful for assessing prognosis, response to ther-
apy, and also for patient monitoring (Esteller, 2008). RCTs dis-
play characteristic and often discriminative chromosomal alter-
ations (Baldewijns et al., 2008). These, however, are not easily
amenable for detection in clinical samples because it requires
tissue culture for karyotyping or FISH analysis using tumor
biopsies. On the contrary, epigenetic alterations carry an enor-
mous potential as speciﬁc cancer biomarkers (Mulero-Navarro
and Esteller, 2008). Furthermore, owing to the reversible nature
of epigenetic alterations, these might constitute attractive thera-
peutic targets, as demonstrated for some hemato-lymphoid neo-
plasms (Rodriguez-Paredes and Esteller, 2011). Thus, in this
review, we address not only the role of epigenetic alterations
in renal carcinogenesis, but also their clinical potential in RCT
management.
EPIGENETIC MECHANISMS AND THEIR DEREGULATION IN
CARCINOGENESIS
Epigenetics might be deﬁned as modiﬁcations of the DNA or
associated proteins, other than DNA sequence variation itself,
that carry information content during cell division (Feinberg
and Tycko, 2004). Presently, three main epigenetic mechanisms
are recognized: DNA methylation, chromatin remodeling/post-
translational histone modiﬁcations, and microRNA (miRNA)
regulation. DNA methylation and chromatin remodeling/post-
translational histone modiﬁcations cause changes in chromatin
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structure that modulate the accessibility of the nuclear tran-
scriptional machinery to speciﬁc DNA sequences. On the other
hand, miRNAs interact with mRNAs regulating translation to
protein.
DNA METHYLATION
The most extensively studied epigenetic mechanism is DNA
methylation which, in mammals, consists on the addition of a
methyl group to cytosines preceding guanines (so-called “CpG
dinucleotides”), a chemical reaction which is catalyzed by DNA
methyltransferases (DNMTs; Goldberg et al., 2007; Lopez-Serra
and Esteller, 2008). These CpG dinucleotides are usually clustered
in DNA stretches called “CpG Islands,” preferentially found at the
regulatory regions of genes, i.e., promoter, untranslated regions,
and exon 1. In a normal cell, CpG methylation is present mainly
in repetitive sequences, retrotransposons, and parasitic sequences,
thus contributing to genetic stability, whereas most of the CpG
islands within promoters remain unmethylated during develop-
ment and even after differentiation, with the notable exception
of some imprinted genes, genes on the silenced copy of X chro-
mosome in females, and tissue-speciﬁc genes (Vaissiere et al.,
2008). Gene silencing associated with methylation of promoter
regions containing CpG islands may be due to an obstruction of
the access of transcription factors or through the promotion of
binding of methylcytosine-binding proteins (MBD), which coop-
erate with DNMTs and histone deacetylases (HDACs; Fraga et al.,
2005; Sharma et al., 2010). Recently, an important role in gene
expression regulation has been also credited to lower density CpG
regions located in the vicinity of CpG islands, the so-called “CpG
island shores”(Doi et al., 2009). These are sequences up to 2 kb dis-
tant from CpG islands, which are associated with gene expression
(Doi et al., 2009; Irizarry et al., 2009). Remarkably, the methy-
lation pattern at CpG island shores is mostly tissue-speciﬁc and
cancer-associated alterations in those patterns occur at sites that
vary normally in tissue differentiation (Irizarry et al., 2009). These
observations are in line with the so-called “epigenetic progenitor
model of cancer” (Feinberg et al., 2006).
Aberrant DNA methylation is probably the best character-
ized cancer-related epigenetic alteration and it is considered by
some as one of the earliest events in the process of tumorigene-
sis (Feinberg et al., 2006). Those aberrations include both global
and gene-speciﬁc hypomethylation as well as gene-speciﬁc CpG
island promoter hypermethylation (Mulero-Navarro and Esteller,
2008; Sharma et al., 2010). The impact of gene-speciﬁc alterations
in DNA methylation depends on the function of the affected
gene and the type of alteration. Whereas promoter hypomethyla-
tion may cause activation of proto-oncogenes, hypermethylation
induces silencing of cancer-related genes with tumor suppres-
sive properties (Feinberg et al., 2006; Sharma et al., 2010). On
the other hand, decrease of global genome methylation (genome-
wide hypomethylation) may lead to genomic instability in repet-
itive sequences, especially at pericentromeric regions, predispos-
ing to abnormal recombination, facilitating translocations, dele-
tions, and chromosomal rearrangements (Ehrlich, 2005; Mulero-
Navarro and Esteller, 2008; Sharma et al., 2010). It was also
demonstrated that aberrant methylation may affect large exten-
sions of DNA in cancer cells, resulting in extensive epigenetic
reprogramming of entire chromosomal regions (Frigola et al.,
2006).
CHROMATIN REMODELING AND HISTONE MODIFICATIONS
Chromatin remodeling refers to covalent and non-covalent mod-
iﬁcations of histones, the proteins that form the core of nucle-
osomes which are the basic unit of chromatin. The N-terminal
tails of histones protrude from the nucleosome and may be sub-
jected to a wide range of post-translational covalent changes
(methylation, acetylation, ubiquitylation, sumoylation, and phos-
phorylation) of speciﬁc amino acid residues and these are involved
in regulation of transcription (Kouzarides, 2007a). This set of
histone modiﬁcations – the so-called “histone code” – deter-
mines the conﬁguration of chromatin, adjusting the accessibility
to effector proteins (Kouzarides, 2007a). For instance, whereas
lysine acetylation is associated with active transcription, lysine
methylation may lead to transcription activation or repression
depending on the residue affected and the degree of modiﬁca-
tion (Kouzarides, 2007a). For example, trimethylation of lysine
4 on histone H3 (H3K4me3) is associated with active transcrip-
tion, whilst H3K27me3 and H3K9me3 are the two chief repressive
marks (Kouzarides, 2007a). There is a large number of enzymes
involved in the addition or removal of the covalent modiﬁca-
tions, including histone acetyltransferases (HATs), deacetylases
(HDACs),methyltransferases (HMTs), and demethylases (HDMs;
Kouzarides, 2007a,b; Shi, 2007). Besides their important role in
regulation of gene expression in somatic cells, covalent histone
modiﬁcations are also critical for embryonic stem cell (ESC)
development and differentiation (Kouzarides, 2007a,b; Shi, 2007).
Indeed, ESCs display bivalent chromatin domains which provide
epigenomic plasticity during normal development. Those biva-
lent chromatin marks consist on the simultaneous occupancy
of trimethylated histone H3 lysine 27 (H3K27me3, a repressive
mark) and of di- and trimethylated histone 3 lysine 4 (H3K4me2
and H3K4me3, which are both active marks) at the promoters of
genes encoding transcription factors that regulate developmen-
tally important genes (Mikkelsen et al., 2007). Thus, neoplastic
transformation would be associated with an alteration of these
marks, leading to silencing of tumor suppressor genes (TSG;
through the loss of H3K4me2 and H3K4me3) with associated
promoter hypermethylation and/or activation of proto-oncogenes
with concomitant loss of methylation (through loss of H3K27me3;
Bloushtain-Qimron et al., 2008; Kondo et al., 2008). On the other
hand,non-covalentmechanism involved in chromatin remodeling
include alterations in nucleosome positioning and incorporation
of histone variants (Henikoff, 2008). It should also be emphasized
that DNA methylation and histone modiﬁcations work in concert
to achieve stable patterns of gene expression (Ballestar andEsteller,
2005; Vaissiere et al., 2008). Indeed, nucleosome remodeling may
be involved in inappropriate gene silencing through the coop-
eration with aberrant DNA methylation and repressive histone
covalentmodiﬁcations (Lin et al., 2007). Concerninghistonemod-
iﬁcations, global loss of both acetylation of lysine 16 (H4K16ac)
and of trimethylation of lysine 20 of histone H4 (H4K20me3) are
commonly found in cancer cells, usually in association with DNA
hypomethylation at repetitive DNA sequences (Fraga et al., 2005).
Loss of H4K16ac correlates with gene silencing (Kapoor-Vazirani
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et al., 2008), but H4K20me3 is normally found in constitutive
heterochromatin regions and other regions that contain silenced
genes (Fullgrabe et al., 2011). Thus, it seems paradoxical that, in
cancer development, the presence of H4K20me3 is also associated
with local silencing of genes (Fullgrabe et al., 2011). In addition,
altered methylation patterns of H3K9 and H3K27 have also been
found in cancer cells (Nguyen et al., 2002; Valk-Lingbeek et al.,
2004). Those modiﬁcations, which result in inappropriate gene
silencing, are accomplished by histone-modifying enzymes. The
expression of some of those enzymes, most notably of HDAC1
and EZH2, is upregulated in several cancers and this is thought to
contribute decisively for cancer initiation and progression (Halki-
dou et al., 2004; Valk-Lingbeek et al., 2004; Song et al., 2005). In
this regard, HDMs, like LSD1 which targets methylated H3K4 and
H3K9, seem also to play an important role in some cancer models
(Metzger et al., 2005; Schulte et al., 2009).
MICRORNAs
MicroRNAs constitute a class of small (∼18–25 nt in length), non-
coding RNAs, which are synthesized (pri-miR) and processed in
the nucleus (pre-miR), and subsequently in the cytoplasm (mature
miR), to ﬁnally incorporate the RISC (RNA-induced silencing
complex) protein complex (Garzon et al., 2009; Guil and Esteller,
2009). MicroRNAs interact with the 3′UTR of target mRNAs,
inducing translational repression or degradation of the latter (Guil
and Esteller, 2009). Interestingly, a speciﬁc miRNA may regulate
multiple mRNAs in the same manner that a single mRNA may
be targeted by multiple miRNAs (Shenouda and Alahari, 2009).
Moreover, a large proportion of human gene transcripts (esti-
matedbetween30 and70%)are known tobe regulatedbymiRNAs,
and these display temporal and tissue-speciﬁc patterns. Thus,
miRNAs are one of the main classes of regulatory human genes,
involved in multiple important cell processes, including cell prolif-
eration, apoptosis, differentiation, development, and metabolism
(Guil and Esteller, 2009).
The altered expression of miRNAs in cancer has been more
recently documented (Lu et al., 2005). Owing to their role as reg-
ulators of mRNA expression, they may act as oncogenes (overex-
pressedmiRNAs that target TSG) orTSG (downregulatedmiRNAs
targeting proto-oncogenes; Guil and Esteller, 2009). Examples of
the former include miR-21, targeting PTEN (Chan et al., 2005),
whereas miR-15 and miR-16, which target BCL2, and let-7, target-
ing RAS, typify the latter (Zhang et al., 2007; Ventura and Jacks,
2009). The mechanisms that lead to altered miRNA expression are
similar to those of regular genes and include ampliﬁcation, dele-
tion,mutation,andpromoter hypermethylation (Guil andEsteller,
2009; Dudziec et al., 2011).
EPIGENETIC ABERRATIONS IN RENAL CELL TUMORS AND
CLINICAL APPLICATIONS
As mentioned in the previous section, the delicate epigenetic
homeostasis that characterizes normal cells is frequently disturbed
in cancer. Indeed, when compared to genetic alterations such as
point mutations, deletions, and ampliﬁcations, epigenetic events
seem to occur much more frequently and at earlier stages (Sharma
et al., 2010; Berdasco and Esteller, 2011). These characteristics not
only endow epigenetic alterations a critical role in tumorigene-
sis, but they also set the basis for their use as cancer biomarkers
for early detection, diagnosis, assessment of prognosis, patient
monitoring, and prediction of response to therapy, as previously
stated (Sharma et al., 2010; Berdasco and Esteller, 2011). In the
next sections, the role of each epigenetic mechanism in renal
cell tumorigenesis, as well as its potential use as biomarker and
therapeutic target, will be discussed.
DNA METHYLATION
Most studies that have investigated promoter hypermethylation in
RCT used either a candidate-gene approach (i.e., cancer-related
genes deregulated through this mechanism in other malignan-
cies and/or genes known to be mutated in familial RCC) or a
functional epigenomic approach, based on genome-wide CpG
methylation analysis platforms (e.g., CpG island arrays). Table 1
provides an overview of the most commonly methylated gene pro-
moters in RCTs according to the cellular pathway in which they
are involved. Studies using the candidate-gene strategy disclosed
promoters with a high frequency (>70% of cases) of hyperme-
thylation, which include APAF1 (Christoph et al., 2006a,b),MDR1
(Costa et al., 2007), and PTGS2 (Costa et al., 2007), those with
intermediate frequency (70–20%), like RASSF1A (Battagli et al.,
2003;Dulaimi et al., 2004;Gonzalgo et al., 2004;Hoque et al., 2004;
Costa et al., 2007; Peters et al., 2007), CDH1 (Esteller et al., 2001;
Morris et al., 2003; Hoque et al., 2004; Costa et al., 2007), DAPK1
(Morris et al., 2003; Christoph et al., 2006a), KRT19 (Paiva et al.,
2011), TIMP3 (Esteller et al., 2001; Battagli et al., 2003; Dulaimi
et al., 2004; Hoque et al., 2004; Costa et al., 2007), UCHL1 (Kagara
et al., 2008; Seliger et al., 2009), PCDH17 (Costa et al., 2011), and
TCF21 (Costa et al., 2011), and infrequently methylated (<20%)
such as APC (Esteller et al., 2001; Dulaimi et al., 2004; Gonzalgo
et al., 2004; Hoque et al., 2004; Costa et al., 2007), CASP-8 (Mor-
ris et al., 2003; Christoph et al., 2006b), CDH13 (Morris et al.,
2003), GSTP1 (Esteller et al., 2001; Dulaimi et al., 2004; Hoque
et al., 2004; Costa et al., 2007), JUP (Breault et al., 2005), MGMT
(Esteller et al., 2001;Morris et al., 2003;Dulaimi et al., 2004;Hoque
et al., 2004; Costa et al., 2007),p14ARF (Esteller et al., 2001;Dulaimi
et al., 2004; Hoque et al., 2004; Costa et al., 2007), p16INK4a (Her-
man et al., 1995; Esteller et al., 2001; Morris et al., 2003; Dulaimi
et al., 2004; Hoque et al., 2004; Costa et al., 2007),RARβ2 (Battagli
et al., 2003; Morris et al., 2003; Dulaimi et al., 2004; Hoque et al.,
2004; Costa et al., 2007), and VHL (Herman et al., 1994; Clifford
et al., 1998; Dulaimi et al., 2004; Banks et al., 2006).
Moreover, because the frequency of point mutations affecting
genes involved in familial RCC is relatively low in the sporadic
cases, except forVHL, the relevance of aberrant promotermethyla-
tion in RCC carcinogenesis has been highlighted (McRonald et al.,
2009). Indeed, several genes, like RASSF1A, SFRP1, DAPK1, and
SPINT2,were consistently found to be silencedbypromoter hyper-
methylation but rarely mutated in sporadic RCC (Morris et al.,
2011).
In this setting, functional epigenomic approaches emerged as
efﬁcient strategies to identify genes whose expression was silenced
by promoter methylation in RCC, through the identiﬁcation of
genes re-expressed after treatment with demethylating drugs in
RCC cell lines and further validated in primary tumor samples.
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Table 1 | Genes frequently methylated in renal cell tumors, according to their function/pathway.
Pathway Gene Designation Frequency (%) Reference
Hormonal response ESR1 Estrogen receptor 1 69–70 Hoque et al. (2004), Costa et al. (2007)
ESR2 Estrogen receptor 2 51–53 Hoque et al. (2004), Costa et al. (2007)
RARβ2 Retinoic acid receptor β2 0–53 Battagli et al. (2003), Morris et al. (2003), Dulaimi et al.
(2004), Hoque et al. (2004), Costa et al. (2007)
Signal transduction DKK2 Dickkopf 2 58 Hirata et al. (2009)
DKK3 Dickkopf 3 50 Urakami et al. (2006)
RASSF1A Ras association domain family protein 1
isoform A
21–88 Battagli et al. (2003), Dulaimi et al. (2004), Gonzalgo
et al. (2004), Hoque et al. (2004), Costa et al. (2007),
Peters et al. (2007)
SFRP1 Secreted frizzled-related protein 1 34–80 Urakami et al. (2006), Costa et al. (2007), Dahl et al.
(2007), Gumz et al. (2007), Morris et al. (2010)
SFRP2 Secreted frizzled-related protein 2 53 Urakami et al. (2006)
SFRP4 Secreted frizzled-related protein 4 53 Urakami et al. (2006)
SFRP5 Secreted frizzled-related protein 5 57 Urakami et al. (2006)
WIF Wnt inhibitory factor 73 Urakami et al. (2006)
Tumor invasion CDH1 E-cadherin 11–59 Esteller et al. (2001), Morris et al. (2003), Dulaimi et al.
(2004), Hoque et al. (2004), Costa et al. (2007)
JUP Junction plakoglobin 91 Breault et al. (2005)
PCDH8 Protocadherin 8 58 Morris et al. (2011)
PCDH17 Protocadherin 17 61 Costa et al. (2011)
SLIT2 Slit homolog 2 (Drosophila) 25 Astuti et al. (2004)
TIMP3 TIMP metallopeptidase inhibitor 3 15–78 Esteller et al. (2001), Battagli et al. (2003), Dulaimi et al.
(2004), Hoque et al. (2004), Costa et al. (2007)
Angiogenesis GREM Gremlin1 20–55 Morris et al. (2010), van Vlodrop et al. (2010)
COL15A1 Collagen type XV alpha-1 53 Morris et al. (2010)
COL1A1 Collagen type I alpha-1 56 Ibanez de Caceres et al. (2006)
Apoptosis APAF1 Apoptotic protease activating factor 1 97–100 Christoph et al. (2006a,b)
DAL1/4.1B Differentially expressed in adenocarci-
noma of the lung
47 Yamada et al. (2006)
DAPK Death-associated Kinase 33–41 Morris et al. (2003), Christoph et al. (2006a)
Others FHIT Fragile histidine triad 52 Costa et al. (2007)
MDR1 Multidrug resistance receptor 1 86 Costa et al. (2007)
PTGS2 Prostaglandin endoperoxidase synthase 2 94 Costa et al. (2007)
TCF21 Transcription factor 21 61 Costa et al. (2011)
This strategy allowed for the discovery of more than 10 candi-
date TSG in RCC: SPINT2 (Morris et al., 2005), IGFBP1, IGFBP3,
COL1A1 (Ibanez de Caceres et al., 2006), UCHL1 (Kagara et al.,
2008), CXCL16, KTN19 (Morris et al., 2008), BNC1, COL14A1,
SFRP1, CST6, and PDLIM4 (Morris et al., 2010). Furthermore,
gene promoters found to be methylated in cell lines but not
in primary tumors (e.g., SST, PTGS1, ISG15, and THY1) might
be important for cancer progression, whereas upregulated genes
following treatment of cell lines with demethylating drugs but
without promoter methylation (e.g.,BAP, IGSF4,RRM2,PMAIP1,
Claudin1, and ICAM ),might be reactivated due to changes in pro-
moter methylation status at upstream regulators (Morris et al.,
2008). The identiﬁcation of new candidate TSG may also be
accomplished using high-throughput CpG methylation analysis
platforms (McRonald et al., 2009) or by isolating methylated
DNA by immunoprecipitation (methylated DNA immunoprecip-
itation, MeDIP) which is then used to perform whole-genome
microarray analysis (Morris et al., 2011). These strategies enabled
the identiﬁcation of several new candidate TSG in RCC, includ-
ing HTR1B, CALCA, IGFBP2, SOX17, COL1A2, BMP4, HS3ST2,
FRZB, TAL1, MCM2, KCNK4, HOXC6, PITX2, SEPT5, IRF7,
CCNA1,HOXA11,TERT,TMEFF2,EPHA3,PGF,MYOD1,MMP2,
TNFRSF10C, PENK, EYA4, MYLK, IRAK3, ZNF215, SMARCB1,
TWIST1, SCGB3A1, and IGFBP7 (McRonald et al., 2009), as
well as ATP5G2, PCDH8, CORO6, KLHL35, QPCT, SCUBE3,
ZSCAN18, CCDC8, and FBN2 (Morris et al., 2011). Deriving
from data collected in several studies, a CpG island methylator
phenotype (CIMP) for RCC has been suggested (Dulaimi et al.,
2004; McRonald et al., 2009), but this topic warrants further
investigation in larger series of cases.
Loss of promoter methylation has been seldom reported in
RCC, although several gene promoters less frequently methylated
in RCC tumor samples compared to normal kidney tissue have
been found, including CARD15 (methylated in 18% of tumors),
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HLA-DRA (24%), SPARC (34%), IL8 (35%), SEPT9 (39%), HLA-
DPB1 (45%), TNFSF10 (47%),VAMP8 (50%), PRKCDBP (55%),
HLA-DPA1 (56%), HDAC1 (58%), BTK (58%), S100A2 (60%),
MPO (61%),CRK (61%),CAPG (61%),NEU1 (69%),ELL (71%;
McRonald et al., 2009), and CA 9 (Cho et al., 2001).
The accumulating data on gene promoter hypermethylation in
RCC supports the development of clinically relevant biomarkers.
Interestingly,differentRCCsubtypes seem todisplay different gene
sets deregulated by promoter hypermethylation (Dulaimi et al.,
2004), and a gene panel (CDH1, PTGS2, and RASSF2) intended
for the discrimination among the most frequent RCT subtypes
in tissue samples has been evaluated (Costa et al., 2007). How-
ever, the application of this approach in an early detection setting
requires testing of clinical samples obtained by minimally inva-
sive or (ideally) non-invasive means, of which urine and serum
stand as the most likely candidates. This has been attempted using
a three-gene panel (APC, RARβ2, RASSF1A) which detected RCC
with high speciﬁcity and sensitivity (Hoque et al., 2004). More-
over, RASSF1A promoter methylation might also prove useful
for tumor surveillance/monitoring of RCC cancer patients (Peters
et al., 2007).
Promoter hypermethylation of some genes has been associated
with clinical and pathological features of tumor aggressiveness
and also to have prognostic relevance. Thus, aberrant promoter
methylation of APAF1 and DAPK1 (Christoph et al., 2006a), as
well as of GREM1 (van Vlodrop et al., 2010) was has been asso-
ciated with aggressive forms of RCC. Moreover, APAF1, DAPK1
(Christoph et al., 2006a), JUP (Breault et al., 2005), PTEN (Kim
et al., 2005), UCHL1 (Kagara et al., 2008), DAL1-4.1B/EPB41L3
(Yamada et al., 2006), BNC1, COL14A1, and SFRP1 (Morris et al.,
2010) promotermethylation have been associatedwith poorer sur-
vival, and most of them (JUP, APAF1, DAPK1, PTEN, DAL1-4.1B,
BNC1, and COL14A1) retained independent prognostic value in
multivariate analysis (Breault et al., 2005; Christoph et al., 2006a;
Morris et al., 2010). In addition, a genome-wide methylation pro-
ﬁle of ccRCC using bacterial artiﬁcial chromosome array-based
methylatedCpG island ampliﬁcation (BAMCA) andunsupervised
hierarchical clustering analysis, found that the clusters obtained
for ccRCC tumor tissues predicted recurrence and these were clin-
icopathological valid since tumors with vascular invasion, renal
vein neoplastic thrombi and higher pathological TNM stage clus-
tered together (Arai et al., 2009). Interestingly, DNA methylation
status of non-cancerous tissues was similar to that of respective
RCC samples, and they were also associated with patient outcome,
suggesting an association of RCC prognosis with precancerous
molecular alterations (Arai et al., 2009). Finally, it has been also
reported that ABCG2/MDR1 gene promoter was methylated in
RCC cell lines, and because this gene is associated with resistance
of cancer cells to chemotherapeutic agents, this biomarker might
become clinically useful for prediction of response to therapy (To
et al., 2008).
Due to the association between promotermethylation and gene
silencing, inhibition of DMNTs has been proposed as a therapeu-
tic strategy to reactivate dormant genes. The nucleoside analog
5-aza-2′-deoxycytidine (DAC), a DNMTs inhibitor (DNMTi) has
been tested in combination with conventional chemotherapeutic
agents (e.g., vinblastine or paclitaxel; Takano et al., 2010; Shang
et al., 2011) in RCC cell lines. A synergistic effect was observed
in both settings, but clinical studies are required to conclusively
demonstrate the therapeutic usefulness of DAC in RCC.
CHROMATIN REMODELING AND HISTONE ONCO-MODIFICATIONS
Most studies on chromatin remodeling and histone onco-
modiﬁcations in RCT have dealt with the relationship with
hypoxia, as well as with the prognostic relevance of those alter-
ations and the potential therapeutic use of histone deacetylase
inhibitors.
It is widely acknowledged that VHL dysfunction is a pivotal
event in ccRCC carcinogenesis (Baldewijns et al., 2008), leading
to constitutive expression of genes that mediate cellular adapta-
tion to hypoxia. This gene encodes for the VHL protein (pVHL),
a substrate recognition component of an E3 ubiquitin ligase com-
plex that targets hypoxia-inducible factors (HIF; e.g., HIF1α and
HIF2α) for ubiquitination and proteasome degradation. HIFs are
constitutively expressed and under normoxic conditions they are
hydroxylated, allowing for their recognition by pVHL and subse-
quent targeting for degradation. Lack of pVHL leads to increased
levels of HIFs and increased expressionof genes involved in cellular
response to hypoxia, promoting angiogenesis, invasion and metas-
tasis, evasion of cell death, and cellular metabolism (Rathmell and
Chen, 2008; Linehan et al., 2010).
Recent evidence unraveled a strong link between hypoxic cel-
lular response and epigenetic regulation, especially histone mod-
iﬁcations, albeit in non-RCC cancer cell lines (Figure 1; Johnson
et al., 2008). Indeed, hypoxia was reported to be associated with
widespread repression of total RNA and mRNA synthesis and
to induce global histone modiﬁcations typically associated with
transcriptional repression (loss of H3K9ac, increase in H3K9me2,
H3K27me2, H3K9me3, H3K27me3, H3K4me1), but also unpre-
dictably with gene activation (increase in H3K14ac, H4R3me2
which may facilitate acetylation of histones associated with acti-
vation of transcription, H3K4me2, H3K4me3, and H3K7me2;
Chen et al., 2006; Johnson et al., 2008). Gene-speciﬁc histone
modiﬁcations included a decrease in H3K9ac and an increase in
H3K9/27me2 at hypoxia-repressed genes, an increase in H3K9ac
and a decrease in H3K9/27me2 at hypoxia-induced genes, and
an increase in H3K4me3 and a decrease in H3K27me3 in all
hypoxia-responsive genes (activated and repressed), suggesting
that repressed chromatin H3K4me3 enriched and H3K27me3
deprived might be rapidly activated when hypoxia is reversed
(Chen et al., 2006; Johnson et al., 2008).
One of the mechanisms that might be involved in altered
epigenetic landscape due to hypoxic effects is the regulation of
Jumonji domain containing histone demethylases by HIF1α, a
critical mediator of hypoxic response (Beyer et al., 2008; Pollard
et al., 2008; Figure 1). Genes encoding Jumonji domain con-
taining 2-oxoglutarate-dependent oxygenases, characterized by a
catalytic Jumonji C (JmjC) domain,were deﬁned as a class of HIF-
responsive hypoxia-inducible genes (Pollard et al., 2008). Histone
demethylases Jumonji domain containing 1A (JMJD1A), Jumonji
domain containing 2B (JMJD2B), and Jumonji domain contain-
ing 2C (JMJD2C) showed consistent patterns of regulation by
hypoxia, especially JMJD1A and JMJD2B, which were found to be
induced by HIF1α but not by HIF2α (Pollard et al., 2008). Since
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FIGURE 1 | Overview of the epigenetic alterations involved in abnormal hypoxic cellular response. See text for details.
HIF upregulation is a feature of ccRCC, the regulation of his-
tone methylation status, and thus of genetic expression, by JmjC
histone demethylases might be another mechanism leading to epi-
genetic changes in RCC carcinogenesis. Indeed, both JMJD1A and
JMJD2B were found to be elevated in a RCC cell line withVHL loss
of function (Beyer et al., 2008), and the expression of JMJD1A was
reported to be higher in RCC cancer tissue than in adjacent nor-
mal renal tissue, mainly in cancer cells surrounding blood vessels,
suggesting that JMJD1A is involved in tumor angiogenesis (Guo
et al., 2011).
In addition, genes encoding for histone-modifying enzymes
have been also reported to be mutated in ccRCC (van Haaften
et al., 2009; Dalgliesh et al., 2010; Table 2). Speciﬁcally, inactivat-
ing mutations were described for SETD2 (H3K36 methyltrans-
ferase), JARID1C/KDM5C (H3K4 demethylase), UTX /KMD6A
(H3K27 demethylase), and MLL2 (an H3K4 methyltransferase;
van Haaften et al., 2009; Dalgliesh et al., 2010). More recently,
mutations in the SWI/SNF chromatin remodeling complex gene
PBRM1 has been identiﬁed in 41% of ccRCCs (Varela et al.,
2011). Interestingly, the induction of the H3K9 speciﬁc demethy-
lases JMJD1A and JMJD2B, which target H3K9me1/me2 and
H3K9me2/me3 respectively, might contribute to an increased
mutation rate in tumors with upregulation of HIF, as H3K9 loss
of methylation promotes chromosomal instability (Beyer et al.,
2008).
The diagnostic potential of histone modiﬁcations and/or his-
tone modiﬁers in RCC has not been explored thus far. They have
been, however, proposed as molecular biomarkers of prognosis,
easily translated to routine pathology because theymay be assessed
by immunohistochemistry in formalin-ﬁxed, parafﬁn-embedded
tissue sections. Several histone marks have been associated with
poor prognosis in RCC, including low H3K4me2, H3K18ac, and
H3K9me2 (Seligson et al., 2009). H3K4me1–3 levels were also
found to be inversely correlated with Fuhrman grade, pT stage,
lymph node involvement and distant metastases, and an H3K4me
score (combining staining levels of H3K4me) was an indepen-
dent factor for RCC progression-free survival (Ellinger et al.,
2010). Similar observations were made for global H3Ac and H4Ac
levels, as well as for H3K9Ac levels in RCCs treated with par-
tial nephrectomy (Minardi et al., 2009), whereas H3K18Ac levels
were an independent predictor of RCC progression after surgery
(Mosashvilli et al., 2010). Concerning histone modiﬁers, EZH2
was found to be upregulated in ccRCC, but this alteration was
unexpectedly associated with a favorable prognosis (Hinz et al.,
2009).
Histone onco-modiﬁcations might also carry therapeutic
implications, as patients with marks of poor prognosis including
low levels of H3K4me2, H3K18ac, and H3K9me2 could bene-
ﬁt from innovative treatments with histone deacetylase inhibitors
(HDACi) Histone onco-modiﬁcations might also carry therapeu-
tic implications, as patients with marks of poor prognosis includ-
ing low levels of H3K4me2,H3K18ac, andH3K9me2 could beneﬁt
from innovative treatments with histone deacetylase inhibitors
(HDACi; Seligson et al., 2009). Some preclinical studies on RCC
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Table 2 | Histone onco-modifications and deregulated modifiers in renal cell tumors.
Chromatin remodeling alterations Reference
Histone post-translational modiﬁcations H3K18Ac, H3K4me1, H3K4me2, H3K4me3 Seligson et al. (2009), Ellinger et al. (2010),
Mosashvilli et al. (2010)
Histone modiﬁers Inactivating mutations of SETD2, JARID1C, UTX, MLL2 van Haaften et al. (2009), Dalgliesh et al. (2010)
EZH2 upregulation Hinz et al. (2009)
cell lines using the HDACi Vorinostat demonstrated an increase
in the anticancer activity of temsirolimus, a mammalian target
of rapamycin (mTOR) inhibitor, through survivin downregula-
tion, leading to increased apoptosis, and enhanced inhibition of
angiogenesis (Mahalingam et al., 2010). Moreover, the proteasome
mediated degradation of Aurora A and Aurora B kinases through
inhibition of HDAC3 and HDAC6 by the HDACi LBH589, was
found to induce G2-M arrest and apoptosis in RCC, highlight-
ing its potential therapeutic use (Cha et al., 2009). Valproic acid
is also an HDACi which causes growth arrest, preventing tumor
cell attachment to endothelium and matrix proteins, and blocking
integrin-dependent signaling (Jones et al., 2009a). The combina-
tion of valproic acid with interferon-alpha enhanced the effects
of the former (Jones et al., 2009a,b) and similar synergism was
found when combined with AEE788, a multiple receptor tyrosine
kinase inhibitor (Juengel et al., 2010). The combination of HDACi
and retinoids might also provide an alternative therapeutic strat-
egy because RARβ2 expression is reduced in RCC, in part owing
to gene-speciﬁc histone hypoacetylation, and its re-expression is
associated with anti-neoplastic effects through the abrogation of
retinoid-resistance (Touma et al., 2005;Wang et al., 2005). Interest-
ingly, this synergistic activitywith retinoids has beendemonstrated
for both HDACi MS-275 (Wang et al., 2005) and trichostatin A
(TSA; Touma et al., 2005) in RCC cell lines.
MICRORNAs
Deregulation of miRNA expression seems to be pivotal for RCC
development and progression (Valera et al., 2011). Indeed, several
miRNA have been found to be deregulated in RCTs, although most
studies have focused mainly on ccRCC. Upregulation of miR-16
(Jung et al., 2009; Zhou et al., 2010), miR-18a (Neal et al., 2010),
miR-20a (Neal et al., 2010), miR-21 (Liu et al., 2010a; Neal et al.,
2010; Zhou et al., 2010), miR-34a (Liu et al., 2010a; Zhou et al.,
2010), miR-34b (Liu et al., 2010a; Zhou et al., 2010), miR-92a
(Valera et al., 2011), miR-155 (Jung et al., 2009; Liu et al., 2010a;
Neal et al., 2010; Zhou et al., 2010), miR-185 (Liu et al., 2010a;
Zhou et al., 2010), miR-210 (Jung et al., 2009; Liu et al., 2010a;
Neal et al., 2010; Zhou et al., 2010), miR-224 (Jung et al., 2009; Liu
et al., 2010a) and let-7 i (Neal et al., 2010; Zhou et al., 2010), and
downregulation of miR-125b (Liu et al., 2010a; Zhou et al., 2010),
miR-141 (Nakada et al., 2008; Jung et al., 2009; Liu et al., 2010a),
miR-133b (Liu et al., 2010a; Zhou et al., 2010), miR-200b (Jung
et al., 2009; Liu et al., 2010a), miR-200c (Nakada et al., 2008; Jung
et al., 2009; Liu et al., 2010a), miR-429 (Jung et al., 2009; Liu et al.,
2010a; Zhou et al., 2010), miR-506 (Zhou et al., 2010; Li et al.,
2011), miR-508-3p (Zhou et al., 2010; Li et al., 2011), miR-509-
5p (Zhou et al., 2010; Li et al., 2011), miR-509-3-5p (Zhou et al.,
2010; Li et al., 2011), miR-510 (Liu et al., 2010a; Zhou et al., 2010;
Li et al., 2011), and miR-514 (Jung et al., 2009; Liu et al., 2010a;
Zhou et al., 2010; Li et al., 2011) are the most consistently reported
alterations.
Renal cell tumors display distinct cytogenetic alterations and
these might cause miRNA deregulation as matching patterns
between deregulated miRNAs and chromosomal aberrations have
been reported in ccRCC (Chow et al., 2010a,b). On the other hand,
miRNA deregulation might serve as an alternative mechanism for
gene expression alterations due to chromosomal aberrations. This
is well illustrated by the miR-204/211 family. Whereas in pRCC
gain of 3q is a common ﬁnding, leading to upregulation of several
genes including C3orf58,CCDC50,DTX3L,PLD1,TRIM59,ECT2,
RAP2B, and SERP1, targeted by miR-204/211 (Liu et al., 2010a),
in ccRCC miR-204/211 downregulation might be the mechanism
causing upregulation of the aforementioned genes, since 3q gain
is rare (Liu et al., 2010a). Moreover, it has been postulated that
most miRNAs are tandemly clustered (Lee et al., 2002; Seitz et al.,
2003), and, accordingly, a co-expression pattern for miRNA fam-
ilies miR-8 (or miR-200), miR-199, and miR-506 has been found
in ccRCC (Li et al., 2011). Another interesting example is pro-
vided by the miR-506 family members miR-506, miR-508-3p,
miR-509-5p, miR-509-3-5p, miR-510, and miR-514, which are
downregulated in ccRCC (Zhou et al., 2010). The corresponding
genes are tandemly clustered in the fragile site Xq27.3 and their
predicted targets are upregulated, including some genes involved
in key signaling pathways like LDHA, HK1, VEGFB, and PSMA1
(Zhou et al., 2010).
Bioinformatics, anti-correlation analysis of miRNA/mRNA lev-
els and functional studies in paired tumorous and normal tissues
are also revealing interesting data on cell function alterations due
to deregulated miRNA in RCTs. Those have showed that deregu-
latedmicroRNAs target genes are commonly involved inmetabolic
(71 target genes of 13 deregulated microRNAs), focal adhesion,
cell adhesion molecules and ECM receptor interactions (30 target
genes of 25 deregulated microRNAs), cell cycle regulation (24 tar-
get genes of 22 deregulated microRNAs), and apoptosis (14 target
genes of 11 deregulated microRNAs) pathways in ccRCC (Zhou
et al., 2010; Table 3).
Furthermore, the miR-200 family is also known to be involved
in epithelial-to-mesenchymal transition, and its downregulation
might contribute to tumor invasion and metastasis (Liu et al.,
2010a; Zhou et al., 2010; Li et al., 2011).
Downregulation of TSG in RCC has been also correlated with
upregulation of oncogenic miRNAs. Indeed, elevated miR-185
was correlated with downregulation of PTEN (with subsequent
activation of PI3K-AKT-mTOR signaling pathway), PTPN13 (a
Fas-associated tyrosine phosphatase that can inhibit PI3K/AKT
signaling, induce apoptosis and suppress the cell survival effects
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Table 3 | MicroRNA deregulation in renal cell tumors, according to their function/pathway and target genes’.
Pathway Upregulated Target gene(s) Reference Downregulated Target gene(s) Reference
Metabolism miR-210 ISCU1/2 Liu et al. (2010a),
Neal et al. (2010),
Zhou et al. (2010)
miR-508-3p LDHA Zhou et al. (2010)
miR-509-3p HK1
Cell Adhesion/invasion NA miR-141 and miR-200c ZEB2/ZFHX1B Nakada et al. (2008)
miR-149 LOX Liu et al. (2010a)
Apoptosis miR-23b POX Liu et al. (2010b) NA
miR-438-3p BBC3/PUMA Veronese et al.
(2010)
VHL-HIF pathway miR-92a VHL Valera et al. (2011) NA
Angiogenesis miR-29a TIS11B Sinha et al. (2009) miR-200bc and miR-429 VEGF Zhou et al. (2010)
Signal transduction miR-34a SFRP1 Liu et al. (2010a) NA
miR-185 PTPN13
miR-224 ERBB4
Other miR-21 SLC12A1, TCF21 Liu et al. (2010a) miR-141 SEMA6A Liu et al. (2010a)
miR-142-3p LRRC2 miR-149 KCNAB1, KCNMA1
BBC3/PUMA, BCL2 binding component 3; ERBB4, v-erb-a erythroblastic leukemia viral oncogene homolog 4; HK1, hexokinase 1; ISCU1/2, iron-sulfur cluster scaf-
fold homolog 1/2; KCNAB1, potassium voltage-gated channel, shaker-related subfamily, beta member 1; KCNMA1, potassium large conductance calcium-activated
channel, subfamily M, alpha member 1; LDHA, lactate dehydrogenase A; LOX, lysyl oxidase; LRRC2, leucine rich repeat containing 2; POX, proline dehydrogenase
(oxidase) 1; PTPN13, protein tyrosine phosphatase, non-receptor type 13; VHL, Von Hippel–Lindau gene; SEMA6A, semaphorin 6A; SFRP1, secreted frizzled-related
protein 1; SLC12A1, solute carrier family 12; TCF21, transcription factor 21; TIS11B, zinc ﬁnger protein 36; C3H type-like 1; VEGF, vascular endothelial growth factor;
ZEB2/ZFHX1B, zinc ﬁnger E-box binding homeobox 2.
of IGF-I), and KCNJ16 (a cell growth-related membrane pro-
tein). In addition, upregulation of miR-34a was correlated with
downregulation of SFRP1 (a Wnt signaling pathway regulator)
whereas miR-224 upregulation was associated with downregula-
tion of ERBB4 (an EGFR family member and putative TSG; Liu
et al., 2010a).
Hypoxic regulation of miRNAs is also emerging as an impor-
tant mechanism implicated in RCC tumorigenesis (Figure 1).
The deregulation of miRNAs in cell lines lacking VHL was been
shown to be either mediated largely via HIF induction (miR-
210 and miR-155) or by HIF independent VHL actions (miR-31,
miR-21, miR-18a, miR-17, let-7i, miR-20a; Neal et al., 2010).
Furthermore, the expression levels of HIF2α and of its down-
stream targets (VEGFα, TGFβ) seems to be regulated by several
members of the miR-200 family (miR-141, miR-200a∗, miR-200b,
miR-200c), and downregulation of miR-200 (or miR-8) fam-
ily and VHL loss activate the HIF pathway (Zhou et al., 2010).
On the other hand, HIF1α can induce miR-210 in many solid
tumors, and miR-210 has been consistently found to be over-
expressed in ccRCC (Jung et al., 2009; Liu et al., 2010a; Neal
et al., 2010; Zhou et al., 2010). Upregulation of miR-210 was
associated with a reduced expression of its target gene ISCU1/2,
which encodes assembly proteins involved in the biogenesis of
[4Fe-4S] and [2Fe-2S] iron-sulfur clusters (Neal et al., 2010).
These are implicated in electron transport and mitochondr-
ial oxidation-reduction reactions, and, thus, downregulation of
ISCU1/2 might contribute to the repression of mitochondrial
proteins and to the anaerobic metabolism in ccRCC (Neal et al.,
2010). Interestingly, hypoxia induced microRNAs have been also
correlated with SLC12A1 and TCF21 downregulation (encoding
cell adhesion proteins) in ccRCC, whose mRNAs were identi-
ﬁed as direct targets of hypoxia induced miR-21 (Liu et al.,
2010a).
Only a few studies addressed the potential use of miRNAs as
RCC biomarkers for detection. In this regard, differential miRNA
expression patterns between neoplastic and non-neoplastic renal
tissues, as well as among different renal tumor subtypes have been
described. The discrimination between ccRCC and normal kidney
tissue might be accomplished by a panel of nine miRs (miR-
21,miR-34a,miR-142-3p,miR-155,miR-185,miR-200c,miR-210,
miR-224, and miR-592; Juan et al., 2010), a combination of miR-
141 and miR-155 (Jung et al., 2009) or through the differential
expression of miR-92a, miR-210, and miR-200c (Valera et al.,
2011).
Concerning distinctive miRNA signatures for each of the
main RCT subtypes, unsupervised hierarchical cluster analysis
of miRNA microarray data showed that tumors derived from
the proximal nephron (ccRCC and pRCC type I) and tumors
derived from the distal nephron (oncocytomas and chRCC) can
be distinguished by their miRNA proﬁle (Valera et al., 2011),
extending previous observations for ccRCC and chRCC (Nakada
et al., 2008). These differential expression patterns of microR-
NAs might be also used to subclassify RCT (Petillo et al., 2009;
Fridman et al., 2010; Youssef et al., 2011). In ccRCC 23 miRNA
are differentially expressed (let-7e, let-7f, let-7g, miR10b, miR-
124, miR-126, miR-138, miR-140-5p, miR-142-5p, miR-144, miR-
184, miR-200c, miR-203, miR-206, miR-210, miR-218, miR-27a,
miR-27b, miR-335, miR-373, miR-378, miR-92a, miR-98; Valera
et al., 2011). However, some miRNAs are characteristic of spo-
radic ccRCC (let-7c, let-7d, miR-1, miR-100, miR-10a, miR-148b,
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Table 4 | Diagnostic and prognostic information in renal cell tumors provided by epigenetic biomarkers.
Detection biomarkers Reference Prognostic/predictive
biomarkers
Reference
DNA methylation APC /RARB2/RASSF1A Hoque et al. (2004) JUP Breault et al. (2005)
RASSF1A Peters et al. (2007) DAL1 Yamada et al. (2006)
APAF1/DAPK1 Christoph et al. (2006b)
RASSF1A/PTGS2/CDH1 Costa et al. (2007) PTEN Kim et al. (2005)
Histone modiﬁcations & modiﬁers NA H3K4me2/H3K18Ac Seligson et al. (2009)
H3K4me1/H3K4me2/H3K4me3 Ellinger et al. (2010)
H3K18Ac Mosashvilli et al. (2010)
miRNA miR-141/miR-155 Jung et al. (2009) miR-32 Petillo et al. (2009)
miR-1233 Wulfken et al. (2011)
NA, not available.
miR-191, miR-199a-3p, miR-19a, miR-215, miR-29b, miR-30c,
miR-363, miR-9) and others of hereditary (Von Hippel–Lindau
syndrome-related) RCC (let-7a, miR-125a-5p, miR-125b, miR-
143, miR-146b-5p, miR-15b, miR-17, miR-193a-5p, miR-193b,
miR-196a, miR-20b, miR-214, miR-23b, miR-32, miR-372; Valera
et al., 2011). Furthermore, ccRCC and pRCC differentially express
27 miRNAs, with miR-203 and miR-424 being more expressed
in ccRCC than in pRCC, and miR-31 and mir-504 being more
expressed in pRCC than in ccRCC (Petillo et al., 2009). Remark-
ably, a similar miRNA expression pattern was reported for chRCC
and oncocytoma. These tumors share 60 miRNAs, with miR-143,
miR-19a, miR-21, miR-29a, miR-181a, and miR-378 unique to
chRCC and mir-146a being preferentially expressed in oncocy-
toma (Valera et al., 2011). Moreover, chRCC displayed higher
levels of miR-203, mir-200b, miR-197, and miR-320 than oncocy-
toma, whereas miR-186 is more highly expressed in oncocytoma
than in chRCC (Petillo et al., 2009). Finally, a recent study which
investigated miRNAs expression levels in sera of RCC patients and
healthy controls, identiﬁed miR-1233 as promising biomarker for
RCC detection and monitoring (Wulfken et al., 2011).
Altered levels of miRNA might also provide prognostic infor-
mation. Whereas miR-155 and miR-21 expression in ccRCC
tumors has been found to correlate with tumor size (Neal et al.,
2010), higher miR-210 levels were found in tumors displaying
higher Fuhrman grade (Valera et al., 2011). In addition, in ccRCC,
overexpression of miR-32 as well as of miR-210, miR-21, let-7i,
and miR-18a correlated with poor survival (Petillo et al., 2009;
Neal et al., 2010) and lower miR-106b levels were associated with
metastatic disease and poorer relapse-free survival (Slaby et al.,
2010). High miR-210 expression was also found in tumors with
lymph node metastasis (Valera et al., 2011), suggesting unique
miRNA signatures in RCC metastasis, distinct from those of
primary tumors (White et al., 2011).
CONCLUSION
The ubiquity of epigenetic alterations in RCT supports their fun-
damental role in renal carcinogenesis. Those alterations not only
provide further insight into the complex mechanisms underly-
ing the genesis and progression of RCT, but they also grant the
opportunity for the development of innovative biomarkers which
might aid in disease detection, diagnosis, assessment of prognosis,
and prediction of response to therapy (Table 4). Finally, owing
to the reversible and plastic nature of epigenetic alterations, these
constitute an attractive target for novel therapeutic approaches
that might tackle one of the most chemoresistant types of human
cancer.
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